<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05065359</url>
  </required_header>
  <id_info>
    <org_study_id>RVT-1201-1005</org_study_id>
    <nct_id>NCT05065359</nct_id>
  </id_info>
  <brief_title>Multiple-Ascending Dose in Japanese Patients Bridging Study</brief_title>
  <official_title>A Randomized, Double-Blinded, Placebo-Controlled, MultipleAscending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rodatristat Ethyl in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altavant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Altavant Sciences, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Altavant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy&#xD;
      Japanese and Caucasian subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, placebo-controlled, multiple-ascending dose study in healthy&#xD;
      Japanese and Caucasian subjects. Two dose levels of rodatristat ethyl, 300 mg twice daily&#xD;
      (BID) and 600 mg BID multiple doses (with a single dose lead in), will be explored in an&#xD;
      ascending dose fashion with a safety review in between (Figure 1 below). Approximately 48&#xD;
      subjects will be enrolled in 4 cohorts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multiple Ascending Dose</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of rodatristat ethyl by incidence of adverse events</measure>
    <time_frame>21 days</time_frame>
    <description>Assessments of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose AUC(0-∞)</measure>
    <time_frame>21 days</time_frame>
    <description>Single dose area under the concentration time curve from time zero (predose-) extrapolated to infinity (AUC(0-∞)) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose AUC(0-t)</measure>
    <time_frame>21 days</time_frame>
    <description>Single dose area under the concentration time curve from time zero to the last detectable time point (AUC(0-t)) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Cmax</measure>
    <time_frame>21 days</time_frame>
    <description>Single dose maximum observed concentration (Cmax) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose tmax</measure>
    <time_frame>21 days</time_frame>
    <description>Single dose time to maximum concentration (tmax) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose t½</measure>
    <time_frame>21 days</time_frame>
    <description>Single dose elimination half-life (t½) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state tmax</measure>
    <time_frame>21 days</time_frame>
    <description>Steady-state tmax of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state Cmax</measure>
    <time_frame>21 days</time_frame>
    <description>Steady-state Cmax of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state Cτ</measure>
    <time_frame>21 days</time_frame>
    <description>Steady-state concentration at end of dosing interval (Cτ) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state Cavg</measure>
    <time_frame>21 days</time_frame>
    <description>Steady-state average concentration at steady state (Cavg) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state AUC(0-τ)</measure>
    <time_frame>21 days</time_frame>
    <description>Steady-state area under the concentration-time curve over the dosing interval at steady-state (AUC(0-τ)) of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state t½</measure>
    <time_frame>21 days</time_frame>
    <description>Steady-state t½ of rodatristat ethyl and metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessment - change from baseline in 5-HIAA concentrations</measure>
    <time_frame>21 days</time_frame>
    <description>PD as assessed by the change from baseline in 5-hydroxyindoleacedtic acid (5-HIAA) concentrations (plasma and 24-hour urinary excretion)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rodatristat Ethyl 300 mg BID - Japanese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rodatristat Ethyl 300 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rodatristat Ethyl 600 mg BID - Japanese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rodatristat Ethyl 600 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rodatristat Ethyl 300 mg BID</intervention_name>
    <description>Tablets, oral, 300 mg, BID 14 days</description>
    <arm_group_label>Rodatristat Ethyl 300 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_label>Rodatristat Ethyl 300 mg BID - Japanese subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rodatristat Ethyl 600 mg BID</intervention_name>
    <description>Tablets, oral, 600 mg, BID 14 days</description>
    <arm_group_label>Rodatristat Ethyl 600 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_label>Rodatristat Ethyl 600 mg BID - Japanese subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets, oral, 0 mg, BID for 14 days</description>
    <arm_group_label>Placebo match for Rodatristat Ethyl 300 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_label>Placebo match for Rodatristat Ethyl 300 mg BID - Japanese subjects</arm_group_label>
    <arm_group_label>Placebo match for Rodatristat Ethyl 600 mg BID - Caucasian subjects</arm_group_label>
    <arm_group_label>Placebo match for Rodatristat Ethyl 600 mg BID - Japanese subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or females aged 18 to 55 years, inclusive&#xD;
&#xD;
          -  A male subject is eligible to participate if he does not have a female partner who is&#xD;
             pregnant or who intends to become pregnant during the study. Male subjects must agree&#xD;
             to use contraception starting at Screening, during the treatment period, and for at&#xD;
             least 100 days after the last dose of Investigational Product (IP), and refrain from&#xD;
             donating sperm during this period.&#xD;
&#xD;
          -  Female subjects of childbearing potential must agree to use contraception starting at&#xD;
             Screening, during the treatment period, and for at least 30 days after the last dose&#xD;
             of IP.&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18 kg/m2 and ≤ 32 kg/m2 at Screening&#xD;
&#xD;
          -  Japanese subjects must have been born in Japan and not have lived outside of Japan &gt;&#xD;
             10 years at the time of Screening, have both parents and grandparents of ethnic&#xD;
             Japanese origin, and have not significantly modified their diets since leaving Japan.&#xD;
&#xD;
          -  Caucasian subjects must be of European or Latin American descent (i.e., White).&#xD;
&#xD;
          -  Capable of giving signed informed consent, able to understand and comply with protocol&#xD;
             requirements, instructions, and protocol related restrictions, and likely to complete&#xD;
             the study as planned.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known pre-existing medical or psychiatric condition that could interfere with the&#xD;
             subject's ability to provide informed consent or participate in study conduct, or that&#xD;
             may confound study findings including, but not limited to a history of clinically&#xD;
             significant gastrointestinal, hematologic, renal, hepatic, bronchopulmonary,&#xD;
             neurological, psychiatric, or cardiovascular disease&#xD;
&#xD;
          -  a. History of Gilbert's Syndrome&#xD;
&#xD;
          -  b. History of depression&#xD;
&#xD;
          -  c. History of any allergy that, in the opinion of the Investigator, contraindicates&#xD;
             participation in the trial&#xD;
&#xD;
          -  Any positive finding on the Columbia-Suicide Severity Rating Scale (C-SSRS).&#xD;
&#xD;
          -  Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding&#xD;
             volume drawn at Screening) of 50 mL to 499 mL of blood within 30 days or more than 499&#xD;
             mL within 56 days prior to Day 1&#xD;
&#xD;
          -  Participation in an investigational drug, vaccine, or device study within 30 days&#xD;
             before IP administration or 90 days for a biologic study&#xD;
&#xD;
          -  Evidence of previous myocardial infarction&#xD;
&#xD;
          -  a. Any conduction abnormality (including but not specific to atrioventricular block&#xD;
             [2nd degree or higher], Wolff Parkinson White syndrome [unless curative ablation&#xD;
             treatment]).&#xD;
&#xD;
          -  b. Sinus pauses &gt; 3 seconds.&#xD;
&#xD;
          -  c. Any significant arrhythmia which, in the opinion of the Investigator and Medical&#xD;
             Monitor, will interfere with the safety for the individual subject.&#xD;
&#xD;
          -  d. Non-sustained or sustained ventricular tachycardia (≥ 3 consecutive ventricular&#xD;
             ectopic beats).&#xD;
&#xD;
          -  Abnormal blood pressure, either low (defined as &lt; 90 mmHg systolic and/or &lt; 50 mmHg&#xD;
             diastolic) or high (defined as &gt; 140 mmHg systolic and/or &gt; 90 mmHg diastolic)&#xD;
&#xD;
          -  Clinically significant abnormalities in laboratory test results (including hepatic and&#xD;
             renal panels, complete blood count, coagulation, chemistry panel, and urinalysis)&#xD;
&#xD;
          -  a. Positive serology for hepatitis B, hepatitis C virus, or human immunodeficiency&#xD;
             virus&#xD;
&#xD;
          -  b. Estimated glomerular filtration rate &lt; 80 mL/min/1.73 m2&#xD;
&#xD;
          -  c. Aspartate aminotransferase, alanine aminotransferase values greater than 1.5 x&#xD;
             upper limit of normal.&#xD;
&#xD;
          -  d. Positive urine test for drugs of abuse&#xD;
&#xD;
          -  e. Positive alcohol test (breath, saliva, or urine)&#xD;
&#xD;
          -  Use of prescription or nonprescription drugs including high dose vitamins, dietary&#xD;
             supplements (including St. John's Wort) within 7 days or 5 half-lives of the&#xD;
             prescription or nonprescription drug (whichever was longer) prior to the first dose of&#xD;
             IP product, unless in the opinion of the Investigator and Sponsor, the medication&#xD;
             would not interfere with the study outcomes or compromise subject safety.&#xD;
&#xD;
          -  Subject unable to abstain from consumption of tryptophan-rich foods 48 hours prior to&#xD;
             admission to the clinic through the Follow-up visit&#xD;
&#xD;
          -  Consumption of grapefruit or Seville oranges or their juices within the 7 days prior&#xD;
             to dosing until collection of the final PK sample.&#xD;
&#xD;
          -  Use of medications associated with QT prolongation within 30 days prior to dosing and&#xD;
             during the study. A list of prohibited medications is provided in an appendix to the&#xD;
             protocol.&#xD;
&#xD;
          -  Subjects unable to abstain from alcohol for 72 hours prior to the start of dosing&#xD;
             through collection of their final PK sample&#xD;
&#xD;
          -  Subjects with a clinical history of or current alcohol abuse defined as an average&#xD;
             weekly intake of more than 21 units for males or 15 units for females (1 unit = 340 mL&#xD;
             beer, 115 mL wine, or 43 mL spirits).&#xD;
&#xD;
          -  Subjects with a clinical history of or current illicit drug use which, in the opinion&#xD;
             of the Investigator, would interfere with the subject's ability to complete the study&#xD;
             and could compromise subject safety and/or the results of the study.&#xD;
&#xD;
          -  Subjects unable to abstain from caffeine, xanthine, or strenuous exercise for 72 hours&#xD;
             prior to dosing until collection of their final PK sample.&#xD;
&#xD;
          -  Subjects who have smoked or used tobacco or nicotine-containing products or&#xD;
             cannabidiol and related products (in all forms) within 3 months prior to the Screening&#xD;
             visit and who are unwilling to refrain from cannabidiol and related products, smoking,&#xD;
             tobacco use, or use of nicotine products and all for the entire duration of the study&#xD;
             (through the Follow-up visit)&#xD;
&#xD;
          -  History of hypersensitivity to rodatristat ethyl, any its components, or any&#xD;
             components in the placebo preparation.&#xD;
&#xD;
          -  Employed as site personnel directly involved with this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jill M Denning</last_name>
    <phone>919-561-6641</phone>
    <email>jill.denning@altavant.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Howard M Lazarus, MD, FCCP</last_name>
    <phone>919-561-6641</phone>
    <email>howard.lazarus@altavant.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>PAH</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

